Compare BXMT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | AUPH |
|---|---|---|
| Founded | 1966 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1998 | 2014 |
| Metric | BXMT | AUPH |
|---|---|---|
| Price | $13.93 | $16.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $21.38 | $17.25 |
| AVG Volume (30 Days) | ★ 2.7M | 1.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | 154.70 | ★ 5075.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ N/A | $31.60 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $13.73 | $10.34 |
| 52 Week High | $20.67 | $19.25 |
| Indicator | BXMT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 57.03 |
| Support Level | $13.73 | $14.67 |
| Resistance Level | $14.84 | $19.25 |
| Average True Range (ATR) | 0.32 | 0.55 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 12.37 | 56.02 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.